Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Mar 2023
Price :
$35
*
At a glance
- Drugs Satralizumab (Primary)
- Indications Neuromyelitis optica
- Focus Registrational; Therapeutic Use
- Acronyms SAkuraStar
- Sponsors Chugai Pharmaceutical; Roche
- 14 May 2022 This trial has been completed in Poland according to European Clinical Trials Database record.
- 26 Apr 2022 Results from SAkuraSky and SAkuraStar assessing the long-term efficacy of satralizumab in patients with aquaporin-4-immunoglobulin-G-seropositive NMOSD, presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 26 Apr 2022 Results of two studies (SAkuraSky and SAkuraStar) assessing long-term safety of satralizumab in patients (pts) with NMOSD during the double-blind periods and open-label extensions of the SAkura studies, presented at the 74th Annual Meeting of the American Academy of Neurology 2022.